ArticleRheumatology (Oxford, England)2026
Comorbidity and mortality in adults with juvenile idiopathic arthritis: a nationwide Norwegian register-based matched cohort study.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThis population-based study assesses comorbidities, autoimmune conditions and all-cause mortality in [1] adults with juvenile idiopathic arthritis (JIA) against general population comparators and [2] adults with JIA with vs without recent disease-modifying anti-rheumatic drug (DMARD) exposure.
methodsWe included adults who, between 2009 and 2024, had ≥2 specialist health contacts with a JIA-specific ICD-10 code in the mandatory Norwegian Patient Registry (NPR). Each case was matched randomly, by age, gender and county of residence, to 10 general population comparators at the time of receiving the second JIA diagnosis in adulthood. We compared 5-year retrospective comorbidity prevalences in descriptive analyses and prospective all-cause mortality in [1] adults with JIA vs comparators and [2] adult JIA with vs without recent DMARD exposure.
resultsAdults with JIA (N = 2932) had higher prevalence than comparators (N = 29 097) of ischemic heart disease excluding myocardial infarction [JIA vs comparators (%): 1.0 vs 0.6], hypertension (3.6 vs 1.4), chronic kidney disease (0.5 vs 0.2), type 1 diabetes (1.7 vs 0.7), coeliac disease (1.4 vs 0.7), autoimmune thyroiditis (0.3 vs 0.1) and autoimmune alopecia (0.4 vs 0.1). Prospective all-cause mortality was higher in JIA than comparators (mortality rate 2.4 vs 1.8 per 1000 person-years). In adult JIA, prevalences of comorbidities and autoimmune conditions as well as all-cause mortality was similar in those with and without recent DMARD exposure.
conclusionIn this study we found an increased 5-year retrospective prevalence of several comorbidities and increased all-cause mortality in adults with JIA compared with population controls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.